Intrauterine Device Extraction Medication

1. Hatcher RA,Trussell J, Nelson AL, Cates W, Stewart F, Kowal D. Contraceptive Technology. 19. New York, NY: Ardent Media; 2007.

2. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010 Aug. 1-44. [QxMD MEDLINE Link].

3. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009 Jan. 79(1):5-14. [QxMD MEDLINE Link].

4. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011 May. 117(5):1105-13. [QxMD MEDLINE Link].

5. Skyla (levonorgestrel-releasing intrauterine system) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. January 2013. Available at [Full Text].

6. Mirena levonorgestrel-releasing intrauterine system [package insert]. Berlex. 2003. Available at [Full Text].

7. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept. 1995 Jun. 11(2):85-95. [QxMD MEDLINE Link].

8. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril. 1984 Jan. 41(1):52-5. [QxMD MEDLINE Link].

9. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999 Nov. 181(5 Pt 1):1263-9. [QxMD MEDLINE Link].

10. Baveja R, Bichille LK, Coyaji KJ, Engineer AD, Gogoi MP, Hazra MN. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception. 1989 Jan. 39(1):37-52. [QxMD MEDLINE Link].

11. Paragard T380A intrauterine copper contraceptive [package insert]. FEI Products. 2003. Available at [Full Text].

12. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception. 1992 Dec. 46(6):575-84. [QxMD MEDLINE Link].

13. [Guideline] Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017 Nov. 130 (5):e251-e269. [QxMD MEDLINE Link]. [Full Text].

14. Alnakash AH. Influence of IUD perceptions on method discontinuation. Contraception. 2008 Oct. 78(4):290-3. [QxMD MEDLINE Link].

15. El-Tagy A, Sakr E, Sokal DC, Issa AH. Safety and acceptability of post-abortal IUD insertion and the importance of counseling. Contraception. 2003 Mar. 67(3):229-34. [QxMD MEDLINE Link].

16. Darney PD, Klaisle CM. Contraception-associated menstrual problems: etiology and management. Dialogues Contracept. 1998 Spring. 5(5):1-6. [QxMD MEDLINE Link].

17. World Health Organization: Medical Eligibility Criteria for Contraceptive Use. 2009.

18. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 2010 Jun 18. 59:1-86. [QxMD MEDLINE Link].

19. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992 Mar 28. 339(8796):785-8. [QxMD MEDLINE Link].

20. Beerthuizen RJ. Pelvic inflammatory disease in intrauterine device users. Eur J Contracept Reprod Health Care. 1996 Sep. 1(3):237-43. [QxMD MEDLINE Link].

21. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006 Feb. 73(2):145-53. [QxMD MEDLINE Link].

22. [Guideline] Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23. 70 (4):1-187. [QxMD MEDLINE Link]. [Full Text].

23. Vidal F, Paret L, Linet T, Tanguy le Gac Y, Guerby P. [Intrauterine contraception: CNGOF Contraception Guidelines]. Gynecol Obstet Fertil Senol. 2018 Nov 11. [QxMD MEDLINE Link].

24. Ozgun MT, Batukan C, Serin IS, Ozcelik B, Basbug M, Dolanbay M. Surgical management of intra-abdominal mislocated intrauterine devices. Contraception. 2007 Feb. 75(2):96-100. [QxMD MEDLINE Link].

25. Verma U, Astudillo-Davalos FE, Gerkowicz SA. Safe and cost-effective ultrasound guided removal of retained intrauterine device: our experience. Contraception. 2015 Feb 21. [QxMD MEDLINE Link].

26. Swenson C, Royer PA, Turok DK, Jacobson JC, Amaral G, Sanders JN. Removal of the LNG IUD when strings are not visible: a case series. Contraception. 2014 Sep. 90(3):288-90. [QxMD MEDLINE Link].

27. Markovitch O, Klein Z, Gidoni Y, Holzinger M, Beyth Y. Extrauterine mislocated IUD: is surgical removal mandatory?. Contraception. 2002 Aug. 66(2):105-8. [QxMD MEDLINE Link].

28. Heinberg EM, McCoy TW, Pasic R. The perforated intrauterine device: endoscopic retrieval. JSLS. 2008 Jan-Mar. 12(1):97-100. [QxMD MEDLINE Link].

29. Haimov-Kochman R, Amsalem H, Adoni A, Lavy Y, Spitz IM. Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: case report. Hum Reprod. 2003 Jun. 18(6):1231-3. [QxMD MEDLINE Link].

30. Adoni A, Ben Chetrit A. The management of intrauterine devices following uterine perforation. Contraception. 1991 Jan. 43(1):77-81. [QxMD MEDLINE Link].

31. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999 Sep. 60(3):155-60. [QxMD MEDLINE Link].

Sarah Hagood Milton, MD Resident Physician, Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System

Disclosure: Nothing to disclose.

Nicole W Karjane, MD Associate Professor, Department of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center

Nicole W Karjane, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, North American Society for Pediatric and Adolescent Gynecology

Disclosure: Received income in an amount equal to or greater than $250 from: Merck<br/>Served as Nexplanon trainer for: Merck.

Christine Isaacs, MD Associate Professor, Department of Obstetrics and Gynecology, Division Head, General Obstetrics and Gynecology, Medical Director of Midwifery Services, Virginia Commonwealth University School of Medicine

Christine Isaacs, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article